Mood, Personality, and Behavior Changes During Treatment with Statins: A Case Series
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Psychiatric adverse drug reactions (ADRs) have been reported with statin use, but the literature regarding statin-associated mood/behavioral changes remains limited. We sought to elicit information germane to natural history and characteristics of central nervous system/behavioral changes in apparent connection with statin and/or cholesterol-lowering drug use, and delineate mechanisms that may bear on an association. Participants (and/or proxies) self-referred with behavioral and/or mood changes in apparent association with statins completed a survey eliciting cholesterol-lowering drug history, character and impact of behavioral/mood effect, time-course of onset and recovery in relation to drug use/modification, co-occurrence of recognized statin-associated ADRs, and factors relevant to ADR causality determination. Naranjo presumptive ADR causality criteria were assessed. Participants (n = 12) reported mood/behavior change that commenced following statin initiation and persisted or progressed with continued use. Reported problems included violent ideation, irritability, depression, and suicide. Problems resolved with drug discontinuation and recurred with rechallenge where attempted. Eight met presumptive criteria for "probable" or "definite" causality; others had additional factors not considered in Naranjo criteria that bear on casual likelihood. (1) Simvastatin 80 mg was followed in 5 days by irritability/depression culminating in suicide in a man in his 40s (Naranjo criteria: possible causality). (2) Simvastatin 10 mg was followed within 2 weeks by depression in a woman in her 50s (probable causality). (3) Atorvastatin 20 mg was followed in ~1 month by depression and irritability/aggression in a male in his 50s (probable causality). (4) Atorvastatin 10 mg was followed in several months by aggression/irritability and depression culminating in suicide in a man in his 40s (possible causality). (5) Fenofibrate + rosuvastatin (unknown dose), later combined with atorvastatin were followed in 1 month by aggression/irritability in a male in his 30s (probable causality). (6) Lovastatin (unknown dose and time-course to reaction) was followed by depression, dyscontrol of bipolar disorder, and suicide attempts in a male in his 40s (possible causality). (7) Atorvastatin 20 mg was followed within 2 weeks by cognitive compromise, and nightmares, depression, and anxiety culminating in suicide in a man in his teens (definite causality). (8) Simvastatin 10 mg was followed (time-course not recalled) by depression, aggression/irritability culminating in suicide in a man in his 60s (possible causality). (9) Simvastatin 20 mg then atorvastatin 10 mg were followed (time-course not provided) by irritability/aggression in a man in his 60s (definite causality). (10) Atorvastatin 10 then 20 then 40 mg were followed shortly after the dose increase by violent ideation and anxiety in a man in his 30s (probable causality). (11) Atorvastatin 20 mg and then simvastatin 20 mg were followed in 2 weeks by aggression/irritability in a man in his 50s (definite causality). (12) Lovastatin, rosuvastatin, atorvastatin, and simvastatin at varying doses were followed as quickly as 1 day by aggression, irritability, and violent ideation in a man in his 40s (definite causality). Most had risk factors for statin ADRs, and co-occurrence of other, recognized statin ADRs. ADRs had implications for marriages, careers, and safety of self and others. These observations support the potential for adverse mood and behavioral change in some individuals with statin use, extend the limited literature on such effects, and provide impetus for further investigation into these presumptive ADRs. Potential mechanisms are reviewed, including hypothesized mechanisms related to oxidative stress and bioenergetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914 · cited 1×
“This employs a point system of positive and negative causality points to estimate the probability of an ADR, with a score C9 deemed to indicate ‘‘definite’’ ADR causality, 5–8 ‘‘probable’’, 1–4 ‘‘possible’’, and B0 ‘‘doubtful’’ [38].”
Muldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990) · BMJ · doi:10.1136/bmj.301.6747.309 · Cited by 960 · cited 1×
“Both naturally low cholesterol and randomized assignment to cholesterol reduction in the pre-statin era have been reported to be linked to increased violent deaths [28, 33, 34], though statin randomization has not [35].”
BackgroundStatin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism
Golomb, B. A., & Evans, M. A. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/0129784-200808060-00004 · Cited by 677
Self-citationThe Missing Voice of Patients in Drug-Safety Reporting
Basch, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmp0911494 · Cited by 646 · cited 16×
“The presence of ADRs and risk factors with a confirmed rela- tion to statin ADRs is consistent with common patho- physiological factors, hypothesized to underlie many statin adverse effects, extending to behavioral effects [39].”
BackgroundInfluentialStatin-associated myopathy with normal creatine kinase levels
Phillips, P. S., Haas, R. H., Bannykh, S., Hathaway, S., Gray, N. L., Kimura, B. J., Vladutiu, G. D., England, J. D. F., & and the Scripps Mercy Clinical Research Center* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-7-200210010-00009 · Cited by 565
Fergusson, D., Doucette, S., Glass, K. C., Shapiro, S., Healy, D., Hebert, P., & Hutton, B. (2005) · BMJ · doi:10.1136/bmj.330.7488.396 · Cited by 510
Lochhead, J. J., McCaffrey, G., Quigley, C. E., Finch, J., DeMarco, K. M., Nametz, N., & Davis, T. P. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.29 · Cited by 334
A Randomized Controlled Trial of Continuous Positive Airway Pressure in Mild Obstructive Sleep Apnea
Barnes, M., Houston, D., Worsnop, C. J., Neill, A. M., Mykytyn, I. J., Kay, A., Trinder, J., Saunders, N. A., McEvoy, R. D., & Pierce, R. J. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.6.2003166 · Cited by 329
Testosterone, aggression, physical, and personality dimensions in normal adolescent males
Olweus, D., Mattsson, Å., Schalling, D., & Low, H. (1980) · Psychosomatic Medicine · doi:10.1097/00006842-198003000-00003 · Cited by 300 · cited 1×
“linked to lower aggression and violence [76, 77].”
Circulating testosterone levels and aggression in adolescent males: a causal analysis
Olweus, D., Mattsson, A., Schalling, D., & Löw, H. (1988) · Psychosomatic Medicine · doi:10.1097/00006842-198805000-00004 · Cited by 272 · cited 1×
“linked to lower aggression and violence [76, 77].”
Cited by
Schultz, B. G., Patten, D. K., & Berlau, D. J. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0110-3 · Cited by 229
“Many of the case reports of cognitive impairment with statins were reported in those with bipolar disorder, schizophrenia, and other behavioral disorders [14, 20, 21].”
BackgroundResultCholesterol Biosynthesis and Uptake in Developing Neurons
Genaro-Mattos, T. C., Anderson, A., Allen, L. B., Korade, Z., & Mirnics, K. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00248 · Cited by 117
Risk of neuropsychiatric adverse effects of lipid-lowering drugs: a mendelian randomization study
Alghamdi, J., Matou-Nasri, S., Alghamdi, F., Alghamdi, S., Alfadhel, M., & Padmanabhan, S. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy060 · Cited by 44
“Specifically, recent interest has been shifted toward potential risk of adverse neuropsychiatric impacts related to statins and other lipid-lowering medications including PCSK9 inhibitors (Tuccori et al., 2014; Cham et al., 2016).”
BackgroundPrevention of suicidal behavior in diabetes: the role of primary care
Sher, L. (2022) · QJM: An International Journal of Medicine · doi:10.1093/qjmed/hcac173 · Cited by 10
Metadata
- Authors
- Cham, S., Koslik, H. J., & Golomb, B. A.
- Venue
- Drug Safety - Case Reports
- Published
- 2015-12-29
- Volume
- 3
- Issue
- 1
- Pages
- 1-1
- ISSN
- 2198-977X (ISSN-L)
- 2199-1162
- OpenAlex
- W2283422148
- Cited by
- 69
- References
- 18
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mood, Personality, and Behavior Changes During Treatment with Statins: A Case Series. https://app.cochat.ai/papers/10.1007/s40800-015-0024-2
- The paper
- Cham, S., Koslik, H. J., & Golomb, B. A. (2016). Mood, Personality, and Behavior Changes During Treatment with Statins: A Case Series. Drug Safety - Case Reports. https://doi.org/10.1007/s40800-015-0024-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.